QLIDA Diagnostics, Inc

Transforming cardiovascular disease diagnosis and management

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded August 2010
  • Employees 3
  • Website qlida.com

Company Summary

QLIDA, Inc. is developing novel diagnostics for cardiovascular disease diagnosis and management enabling:
• Ultrasensitive detection of cardiac biomarkers from blood
• Point of care format with 100x increased sensitivity over standard of care
• Novel biomarker platform with greater specificity and sensitivity
Other applications include clinical research and the management of chronic disease.
The QLIDA technology was developed at Drexel.

Team

  • Michel Boyce-Jacino
    President and CEO

    Michael Boyce-Jacino, Ph.D., is founder and CEO of QLIDA Diagnostics, a spin-out of Drexel University focused on rapid, emergency room-based diagnosis of heart attacks using an ultrasensitive detector. He was founding CEO of BioNanomatrix, Inc. a spinout from Princeton University which is commercializing nanofabricated single molecule imagers for research and diagnostics and VP Genomics for Beckman Coulter.

  • Michael Kochersperger
    VP Engineering

    Michael Kochersperger has developed many research and clinical instruments at companies such as Applied Biosystems, Orchid Biosciences, BioNanomatrix and New Brunswick Scientific

  • Michael Neidrauer
    Chief Scientific Officer

    Mike is an Assistant Research Professor in the School of Biomedical Engineering, Science & Health Systems at Drexel University and a co-inventor of the QLIDA technology.

  • Michael Boyce-Jacino

Advisors

  • Jeff Bodle, Morgan Lewis
    Lawyer
    Unconfirmed

Previous Investors

  • Ben Franklin Technology Partners
    Unconfirmed
    NetScientific America
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free